Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2017-09, Vol.28, p.v429-v430
Hauptverfasser: Dummer, R., Ascierto, P.A., Gogas, H., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J.W.B., Yamazaki, N., Loquai, C., de Parseval, L.A., Pickard, M., Sandor, V., Robert, C., Flaherty, K.T.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page v430
container_issue
container_start_page v429
container_title Annals of oncology
container_volume 28
creator Dummer, R.
Ascierto, P.A.
Gogas, H.
Arance, A.
Mandala, M.
Liszkay, G.
Garbe, C.
Schadendorf, D.
Krajsová, I.
Gutzmer, R.
Chiarion Sileni, V.
Dutriaux, C.
de Groot, J.W.B.
Yamazaki, N.
Loquai, C.
de Parseval, L.A.
Pickard, M.
Sandor, V.
Robert, C.
Flaherty, K.T.
description
doi_str_mv 10.1093/annonc/mdx377.002
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdx377_002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753420384787</els_id><sourcerecordid>S0923753420384787</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1852-d6ac352f50450bddf8cc5f66108a9a7c922175d2542ba64b0c2ac0953051ac7e3</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhi0EEqXwA9g80iGtP-IkhqmNWqhUWlToHF0cRxglTmWnFQz8d1LCzHTS3fuc7h6EbikZUyL5BKxtrJrUxSeP4zEh7AwNqIhkkJCQnqMBkYwHseDhJbry_oMQEkkmB-h7q_2haj1uSpxuVrvn2e4Vv4BrMbvHU7x_B68xx60zUJ0y2qrGQamtyfHdfJ1uRnhfHTzOjTW1bs1vf7ZcL0f4qJ3vJqcQNhbPttNFUB9asC2udQW2qeEaXZRQeX3zV4dot5i_pU_BavO4TKerQNFEsKCIQHHBSkFCQfKiKBOlRBlFlCQgIVaSMRqLgomQ5RCFOVEMFJGCE0FBxZoPEe33Ktd473SZ7Z2pwX1llGQnf1nvL-v9ZZ2_jnnoGd0ddjTaZV6Z7n1dGKdVmxWN-Yf-AUOOeHQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Dummer, R. ; Ascierto, P.A. ; Gogas, H. ; Arance, A. ; Mandala, M. ; Liszkay, G. ; Garbe, C. ; Schadendorf, D. ; Krajsová, I. ; Gutzmer, R. ; Chiarion Sileni, V. ; Dutriaux, C. ; de Groot, J.W.B. ; Yamazaki, N. ; Loquai, C. ; de Parseval, L.A. ; Pickard, M. ; Sandor, V. ; Robert, C. ; Flaherty, K.T.</creator><creatorcontrib>Dummer, R. ; Ascierto, P.A. ; Gogas, H. ; Arance, A. ; Mandala, M. ; Liszkay, G. ; Garbe, C. ; Schadendorf, D. ; Krajsová, I. ; Gutzmer, R. ; Chiarion Sileni, V. ; Dutriaux, C. ; de Groot, J.W.B. ; Yamazaki, N. ; Loquai, C. ; de Parseval, L.A. ; Pickard, M. ; Sandor, V. ; Robert, C. ; Flaherty, K.T.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx377.002</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2017-09, Vol.28, p.v429-v430</ispartof><rights>2017 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1852-d6ac352f50450bddf8cc5f66108a9a7c922175d2542ba64b0c2ac0953051ac7e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Dummer, R.</creatorcontrib><creatorcontrib>Ascierto, P.A.</creatorcontrib><creatorcontrib>Gogas, H.</creatorcontrib><creatorcontrib>Arance, A.</creatorcontrib><creatorcontrib>Mandala, M.</creatorcontrib><creatorcontrib>Liszkay, G.</creatorcontrib><creatorcontrib>Garbe, C.</creatorcontrib><creatorcontrib>Schadendorf, D.</creatorcontrib><creatorcontrib>Krajsová, I.</creatorcontrib><creatorcontrib>Gutzmer, R.</creatorcontrib><creatorcontrib>Chiarion Sileni, V.</creatorcontrib><creatorcontrib>Dutriaux, C.</creatorcontrib><creatorcontrib>de Groot, J.W.B.</creatorcontrib><creatorcontrib>Yamazaki, N.</creatorcontrib><creatorcontrib>Loquai, C.</creatorcontrib><creatorcontrib>de Parseval, L.A.</creatorcontrib><creatorcontrib>Pickard, M.</creatorcontrib><creatorcontrib>Sandor, V.</creatorcontrib><creatorcontrib>Robert, C.</creatorcontrib><creatorcontrib>Flaherty, K.T.</creatorcontrib><title>Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAQhi0EEqXwA9g80iGtP-IkhqmNWqhUWlToHF0cRxglTmWnFQz8d1LCzHTS3fuc7h6EbikZUyL5BKxtrJrUxSeP4zEh7AwNqIhkkJCQnqMBkYwHseDhJbry_oMQEkkmB-h7q_2haj1uSpxuVrvn2e4Vv4BrMbvHU7x_B68xx60zUJ0y2qrGQamtyfHdfJ1uRnhfHTzOjTW1bs1vf7ZcL0f4qJ3vJqcQNhbPttNFUB9asC2udQW2qeEaXZRQeX3zV4dot5i_pU_BavO4TKerQNFEsKCIQHHBSkFCQfKiKBOlRBlFlCQgIVaSMRqLgomQ5RCFOVEMFJGCE0FBxZoPEe33Ktd473SZ7Z2pwX1llGQnf1nvL-v9ZZ2_jnnoGd0ddjTaZV6Z7n1dGKdVmxWN-Yf-AUOOeHQ</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Dummer, R.</creator><creator>Ascierto, P.A.</creator><creator>Gogas, H.</creator><creator>Arance, A.</creator><creator>Mandala, M.</creator><creator>Liszkay, G.</creator><creator>Garbe, C.</creator><creator>Schadendorf, D.</creator><creator>Krajsová, I.</creator><creator>Gutzmer, R.</creator><creator>Chiarion Sileni, V.</creator><creator>Dutriaux, C.</creator><creator>de Groot, J.W.B.</creator><creator>Yamazaki, N.</creator><creator>Loquai, C.</creator><creator>de Parseval, L.A.</creator><creator>Pickard, M.</creator><creator>Sandor, V.</creator><creator>Robert, C.</creator><creator>Flaherty, K.T.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201709</creationdate><title>Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma</title><author>Dummer, R. ; Ascierto, P.A. ; Gogas, H. ; Arance, A. ; Mandala, M. ; Liszkay, G. ; Garbe, C. ; Schadendorf, D. ; Krajsová, I. ; Gutzmer, R. ; Chiarion Sileni, V. ; Dutriaux, C. ; de Groot, J.W.B. ; Yamazaki, N. ; Loquai, C. ; de Parseval, L.A. ; Pickard, M. ; Sandor, V. ; Robert, C. ; Flaherty, K.T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1852-d6ac352f50450bddf8cc5f66108a9a7c922175d2542ba64b0c2ac0953051ac7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dummer, R.</creatorcontrib><creatorcontrib>Ascierto, P.A.</creatorcontrib><creatorcontrib>Gogas, H.</creatorcontrib><creatorcontrib>Arance, A.</creatorcontrib><creatorcontrib>Mandala, M.</creatorcontrib><creatorcontrib>Liszkay, G.</creatorcontrib><creatorcontrib>Garbe, C.</creatorcontrib><creatorcontrib>Schadendorf, D.</creatorcontrib><creatorcontrib>Krajsová, I.</creatorcontrib><creatorcontrib>Gutzmer, R.</creatorcontrib><creatorcontrib>Chiarion Sileni, V.</creatorcontrib><creatorcontrib>Dutriaux, C.</creatorcontrib><creatorcontrib>de Groot, J.W.B.</creatorcontrib><creatorcontrib>Yamazaki, N.</creatorcontrib><creatorcontrib>Loquai, C.</creatorcontrib><creatorcontrib>de Parseval, L.A.</creatorcontrib><creatorcontrib>Pickard, M.</creatorcontrib><creatorcontrib>Sandor, V.</creatorcontrib><creatorcontrib>Robert, C.</creatorcontrib><creatorcontrib>Flaherty, K.T.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dummer, R.</au><au>Ascierto, P.A.</au><au>Gogas, H.</au><au>Arance, A.</au><au>Mandala, M.</au><au>Liszkay, G.</au><au>Garbe, C.</au><au>Schadendorf, D.</au><au>Krajsová, I.</au><au>Gutzmer, R.</au><au>Chiarion Sileni, V.</au><au>Dutriaux, C.</au><au>de Groot, J.W.B.</au><au>Yamazaki, N.</au><au>Loquai, C.</au><au>de Parseval, L.A.</au><au>Pickard, M.</au><au>Sandor, V.</au><au>Robert, C.</au><au>Flaherty, K.T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma</atitle><jtitle>Annals of oncology</jtitle><date>2017-09</date><risdate>2017</risdate><volume>28</volume><spage>v429</spage><epage>v430</epage><pages>v429-v430</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdx377.002</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2017-09, Vol.28, p.v429-v430
issn 0923-7534
1569-8041
language eng
recordid cdi_crossref_primary_10_1093_annonc_mdx377_002
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A25%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Results%20of%20COLUMBUS%20Part%202:%20A%20phase%203%20trial%20of%20encorafenib%20(ENCO)%20plus%20binimetinib%20(BINI)%20versus%20ENCO%20in%20BRAF-mutant%20melanoma&rft.jtitle=Annals%20of%20oncology&rft.au=Dummer,%20R.&rft.date=2017-09&rft.volume=28&rft.spage=v429&rft.epage=v430&rft.pages=v429-v430&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx377.002&rft_dat=%3Celsevier_cross%3ES0923753420384787%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753420384787&rfr_iscdi=true